# Microbot Medical Inc.: financial statements, quarterly

MBOT · Nasdaq · CIK 883975 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mbot.md) · [Financials](/companies/mbot/financials.md) · [Filings](/companies/mbot/filings.md) · [Insiders](/companies/mbot/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mbot/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [105](/filings/0001493152-26-022792.md) | [241](/filings/0001493152-26-037009.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [103](/filings/0001493152-26-022792.md) | [884](/filings/0001493152-26-037009.md) |
| Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [2.0](/filings/0001493152-26-022792.md) | [(643)](/filings/0001493152-26-037009.md) |
| Research and development | $k | [1,612](/filings/0001493152-24-045136.md) | [1,130 d](/filings/0001641172-25-000614.md) | [1,169](/filings/0001641172-25-010277.md) | [1,417](/filings/0001641172-25-023206.md) | [2,060](/filings/0001493152-25-021929.md) | [1,984 d](/filings/0001493152-26-012935.md) | [1,459](/filings/0001493152-26-022792.md) | [2,111](/filings/0001493152-26-037009.md) | [1,171](/filings/0001493152-25-021929.md) | [1,542 d](/filings/0001493152-26-012935.md) | [1,293](/filings/0001493152-26-022792.md) | [1,861](/filings/0001493152-26-037009.md) |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | [1,562](/filings/0001493152-26-022792.md) | [1,612](/filings/0001493152-26-037009.md) | not reported | not reported | [3,029](/filings/0001493152-26-022792.md) | [3,684](/filings/0001493152-26-037009.md) |
| Operating income | $k | [(2,544)](/filings/0001493152-24-045136.md) | [(2,068) d](/filings/0001641172-25-000614.md) | [(2,384)](/filings/0001641172-25-010277.md) | [(2,511)](/filings/0001641172-25-023206.md) | [(3,300)](/filings/0001493152-25-021929.md) | [(3,430) d](/filings/0001493152-26-012935.md) | [(3,021)](/filings/0001493152-26-022792.md) | [(3,723)](/filings/0001493152-26-037009.md) | [(3,861)](/filings/0001493152-25-021929.md) | [(4,138) d](/filings/0001493152-26-012935.md) | [(4,320)](/filings/0001493152-26-022792.md) | [(6,188)](/filings/0001493152-26-037009.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,446)](/filings/0001493152-24-045136.md) | [(3,154) d](/filings/0001641172-25-000614.md) | [(2,371)](/filings/0001493152-25-021929.md) | [(2,465)](/filings/0001493152-25-021929.md) | [(3,215)](/filings/0001493152-25-021929.md) | [(3,392) d](/filings/0001493152-26-012935.md) | [(2,601)](/filings/0001493152-26-037009.md) | [(3,500)](/filings/0001493152-26-037009.md) | [(3,577)](/filings/0001493152-25-021929.md) | [(3,464) d](/filings/0001493152-26-012935.md) | [(3,671)](/filings/0001493152-26-037009.md) | [(5,627)](/filings/0001493152-26-037009.md) |
| Diluted EPS | $ per share | [(0.21)](/filings/0001493152-24-045136.md) | not reported | [(0.17)](/filings/0001641172-25-010277.md) | [(0.17)](/filings/0001641172-25-023206.md) | [(0.20)](/filings/0001493152-25-021929.md) | not reported | [(0.08)](/filings/0001493152-26-022792.md) | [(0.10)](/filings/0001493152-26-037009.md) | [(0.07)](/filings/0001493152-25-021929.md) | not reported | [(0.05)](/filings/0001493152-26-022792.md) | [(0.08)](/filings/0001493152-26-037009.md) |
| Basic EPS | $ per share | [(0.21)](/filings/0001493152-24-045136.md) | not reported | [(0.17)](/filings/0001641172-25-010277.md) | [(0.17)](/filings/0001641172-25-023206.md) | [(0.20)](/filings/0001493152-25-021929.md) | not reported | [(0.08)](/filings/0001493152-26-022792.md) | [(0.10)](/filings/0001493152-26-037009.md) | [(0.07)](/filings/0001493152-25-021929.md) | not reported | [(0.05)](/filings/0001493152-26-022792.md) | [(0.08)](/filings/0001493152-26-037009.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.3](/filings/0001493152-23-041069.md) | [2.5](/filings/0001641172-25-000614.md) | [1.2](/filings/0001493152-24-019535.md) | [2.5](/filings/0001641172-25-023206.md) | [0.5](/filings/0001493152-25-021929.md) | [3.1](/filings/0001493152-26-012935.md) | [3.2](/filings/0001641172-25-010277.md) | [4.1](/filings/0001493152-26-037009.md) | [6.7](/filings/0001493152-25-021929.md) | [3.9](/filings/0001493152-26-037009.md) | [3.7](/filings/0001493152-26-022792.md) | [3.2](/filings/0001493152-26-037009.md) |
| Current assets | $m | [8.4](/filings/0001493152-23-041069.md) | [7.9](/filings/0001641172-25-000614.md) | [7.0](/filings/0001493152-24-019535.md) | [7.1](/filings/0001493152-24-032031.md) | [5.0](/filings/0001493152-24-045136.md) | [5.8](/filings/0001493152-26-012935.md) | [30.7](/filings/0001641172-25-010277.md) | [32.9](/filings/0001641172-25-023206.md) | [80.8](/filings/0001493152-25-021929.md) | [79.8](/filings/0001493152-26-037009.md) | [76.5](/filings/0001493152-26-022792.md) | [72.2](/filings/0001493152-26-037009.md) |
| Total assets | $m | [8.9](/filings/0001493152-23-041069.md) | [8.3](/filings/0001641172-25-000614.md) | [7.4](/filings/0001493152-24-019535.md) | [7.4](/filings/0001493152-24-032031.md) | [5.2](/filings/0001493152-24-045136.md) | [6.0](/filings/0001493152-26-012935.md) | [30.9](/filings/0001641172-25-010277.md) | [33.1](/filings/0001641172-25-023206.md) | [81.8](/filings/0001493152-25-021929.md) | [81.5](/filings/0001493152-26-037009.md) | [78.1](/filings/0001493152-26-022792.md) | [73.4](/filings/0001493152-26-037009.md) |
| Current liabilities | $m | [1.5](/filings/0001493152-23-041069.md) | [3.8](/filings/0001641172-25-000614.md) | [1.2](/filings/0001493152-24-019535.md) | [1.3](/filings/0001493152-24-032031.md) | [1.4](/filings/0001493152-24-045136.md) | [2.5](/filings/0001493152-26-012935.md) | [1.9](/filings/0001641172-25-010277.md) | [2.7](/filings/0001641172-25-023206.md) | [2.9](/filings/0001493152-25-021929.md) | [3.4](/filings/0001493152-26-037009.md) | [3.4](/filings/0001493152-26-022792.md) | [3.9](/filings/0001493152-26-037009.md) |
| Total liabilities | $m | [1.5](/filings/0001493152-23-041069.md) | [3.8](/filings/0001641172-25-000614.md) | [1.2](/filings/0001493152-24-019535.md) | [1.4](/filings/0001493152-24-032031.md) | [1.4](/filings/0001493152-24-045136.md) | [2.5](/filings/0001493152-26-012935.md) | [1.9](/filings/0001641172-25-010277.md) | [2.8](/filings/0001641172-25-023206.md) | [3.5](/filings/0001493152-25-021929.md) | [4.0](/filings/0001493152-26-037009.md) | [4.0](/filings/0001493152-26-022792.md) | [4.4](/filings/0001493152-26-037009.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [7.4](/filings/0001493152-24-045136.md) | [4.5](/filings/0001493152-26-012935.md) | [6.2](/filings/0001493152-25-021929.md) | [6.1](/filings/0001493152-25-021929.md) | [3.8](/filings/0001493152-25-021929.md) | [3.5](/filings/0001493152-26-037009.md) | [29.0](/filings/0001493152-26-037009.md) | [30.4](/filings/0001493152-26-037009.md) | [78.2](/filings/0001493152-25-021929.md) | [77.6](/filings/0001493152-26-037009.md) | [74.1](/filings/0001493152-26-037009.md) | [68.9](/filings/0001493152-26-037009.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,655) d](/filings/0001493152-24-045136.md) | [(1,821) d](/filings/0001641172-25-000614.md) | [(2,420)](/filings/0001641172-25-010277.md) | [(1,957) d](/filings/0001641172-25-023206.md) | [(2,759) d](/filings/0001493152-25-021929.md) | [(1,691) d](/filings/0001493152-26-012935.md) | [(2,874)](/filings/0001493152-26-022792.md) | [(2,573) d](/filings/0001493152-26-037009.md) | [(3,841) d](/filings/0001493152-25-021929.md) | [(3,758) d](/filings/0001493152-26-012935.md) | [(5,053)](/filings/0001493152-26-022792.md) | [(4,989) d](/filings/0001493152-26-037009.md) |
| Capital expenditure | $k | [28.0 d](/filings/0001493152-24-045136.md) | [(5.0) d](/filings/0001641172-25-000614.md) | [14.0](/filings/0001641172-25-010277.md) | [4.0 d](/filings/0001641172-25-023206.md) | [0.0 d](/filings/0001493152-25-021929.md) | [7.0 d](/filings/0001493152-26-012935.md) | [13.0](/filings/0001493152-26-022792.md) | [9.0 d](/filings/0001493152-26-037009.md) | [13.0 d](/filings/0001493152-25-021929.md) | [25.0 d](/filings/0001493152-26-012935.md) | [108](/filings/0001493152-26-022792.md) | [142 d](/filings/0001493152-26-037009.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [7.1](/filings/0001493152-23-041069.md) | [8.0](/filings/0001493152-24-019535.md) | [9.2](/filings/0001493152-24-032031.md) | [11.7](/filings/0001493152-24-045136.md) | [14.1](/filings/0001641172-25-010277.md) | [14.8](/filings/0001641172-25-023206.md) | [16.5](/filings/0001493152-25-021929.md) | [31.1](/filings/0001493152-26-022792.md) | [36.5](/filings/0001493152-26-037009.md) | [48.1](/filings/0001493152-25-021929.md) | [67.2](/filings/0001493152-26-022792.md) | [67.2](/filings/0001493152-26-037009.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 67,164,801 at 2026-08-11, from the cover of the [10-Q filed 2026-08-11](/filings/0001493152-26-037009.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.